Impact of EPA and DHA Supplementation on Plasma Biomarkers of Inflammation (n3)

Plain-language summary

This study investigated the effect of EPA and DHA (omega-3 fatty acid) supplements on markers of inflammation in the blood. Participants received high DHA, high EPA, or placebo; the study included men and women aged 18-70 with abdominal obesity. The study was carried out as a non-phase study and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Not Applicable

Status

Completed

Sponsor

Laval University

Intervention

High DHA, High EPA, Placebo

Start date

3/1/2013

Estimated completion

12/1/2017

Countries

Canada

Related genes

Locations

• Québec, Canada

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Men and women aged between 18 and 70 years with abdominal obesity as defined by the International Diabetes Federation criteria and a measure of plasma CRP \>1 mg/L
* Stable body weight for at least 3 months prior to randomization.
* Pre-menopausal women with regular menstrual cycle (25-35 days)

Exclusion Criteria:

* Plasma CRP \> 10 mg/L at screening
* Extreme dyslipidemias such as familial hypercholesterolemia
* Previous history of cardiovascular disease (coronary heart disease, cerebrovascular disease or peripheral arterial disease)
* Subjects taking medications known to affect inflammation (e.g. steroids, binging alcohol)
* Subjects taking LCn-3PUFA supplements within 2 months of study onset.